Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. In the next year, analysts predict that Revenue will reach C$253.83M - an increase of 3.50%. That was below AbbVie stock analysts' view for $14.16. That is a significant difference because at a forward P/E of 10x AbbVie stock looks like a solid buy opportunity, but at a P/E of 20x, when we consider the risk/challenge of Humira's LOE, prospective investors may prefer to maintain a watching brief as opposed to opening a position. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. Their ABBV share price forecasts range from $140.00 to $200.00. Data from two Phase 3 induction studies and one maintenance study supported the approval. The company is focused on research and has a number of collaborations and partnerships to that end. AbbVie is a leader in ESG and sustainability. Shares are consolidating with a buy. outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . The pharma industry witnessed solid growth amid the pandemic. Teliso V is an antibody drug conjugate and a c-Met inhibitor. One share of ABBV stock can currently be purchased for approximately $156.06. As I have mentioned in previous notes, however, the gains owe more to price hikes than sales volumes, and come 2023 and the LOE, even AbbVie admits the blow to revenues will be substantial. Receive regular, detailed analysis focused on biotech and healthcare stocks. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. Gene therapies have been a long time coming, having first been popularized in the early noughties. Receive ABBV Stock News and Ratings via Email. Earnings for AbbVie are expected to decrease by -0.55% in the coming year, from $11.00 to $10.94 per share. This means that . AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. In other words, no Humira, no problem! The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. View our ABBV earnings forecast. Always do your own research on a stocks price performance and predictions before making an investment. AbbVie income statement forecast (My table and assumptions). Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. RHHBY vs. ABBV: Which Stock Is the Better Value Option? Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Management puts this down to "delayed market recovery for new patients starting therapy in Chronic Lymphocytic Leukemia ("CLL") and increasing competition" and has downgraded its FY22 guidance as a result. In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. The company didn't offer a . See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. In this post I model AbbVie product sales to 2030 - including pipeline assets - and use discounted cash flow analysis to calculate a present day share price target. AbbVie will have to drop its price point to compete with the generics however, plus there is the 10% of the market it is not covered for, so an overall 20% decline in revenues in 2023 seems accurate. I'm on twitter @edmundingham. AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. What is ABBV's Earnings Per Share (EPS) forecast for 2023-2025? on the strength of its future rather than present portfolio. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. The stock projection varied from the low price target of $135 to the high of $200. That reflects uncertainty about what the future holds for AbbVie. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. ET comments Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. What other stocks do shareholders of AbbVie own? There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. For the next year, analysts predict that Free Cash Flow will reach 6.91B - an increase of 1.94%. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. I write about Biotech, Pharma and Healthcare stocks and share investment tips. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. American Consumer News, LLC dba MarketBeat 2010-2023. Past performance is no guarantee of future results. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. Within the oncology division sales of Imbruvica fell 17% year-on-year. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. In 2022, the company will most likely boast 12 "blockbuster" (>$1bn per annum) selling assets, driving ~$48bn of revenues between them, with Humira being the only drug that faces a near term patent expiry, whilst AbbVie is promising at least 6 or 7 major new product launches by 2026. The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. Since then, however, the stock price has fallen 18% to its current price of $142.6. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. View ABBV analyst ratings or view top-rated stocks. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Please. ABBV has several positive factors pushing its price performance. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". On average, they expect the company's stock price to reach $161.12 in the next twelve months. The dividend payout ratio of AbbVie is 89.56%. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. AbbVie says it will pay down debt of $4bn in 2023, which will "bring cumulative debt pay down ~$34bn", but the company is heavily reliant on maintaining an investment grade rating. What is AbbVie's stock price forecast for 2023? This year is off to a strong start. This has been in spite of a string of macroeconomic headwinds such as the ongoing Russia-Ukraine war that has contributed to record high inflation in the US and the UK, and the companys psoriatic arthritis drug Adalimumab, known as Humira, facing biosimilar rivals in the US from 2023. For the next nine years, the forecast is for Revenue to grow by 3.57%. AbbVie is a leading dividend payer. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. This could present more profit potential for drugmakers as well as investors. Please. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. Receive regular, detailed analysis focused on biotech and healthcare stocks. The average price target represents a 6.33% change from the last price of $153.90. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. The company has a robust pipeline of new products that are in some stage of clinical trials. AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE. AbbVie has been increasing its dividend for 51 years. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647.